Increasing Transparency in Generic Drug Applications Act of 2022
Summary
Increasing Transparency in Generic Drug Applications Act of 2022 This bill requires the Food and Drug Administration to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why).
Bill status
in committee
1 of 4 stages cleared
Introduction
Mar 2022
Committee Review
Floor Vote
President
Introduced Mar 9, 2022
Last action Mar 10, 2022
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
3
Key actions
0
Committee
2
Mar 10, 2022
Committee
Referred to the Subcommittee on Health.
lower
Mar 9, 2022
Committee
Referred to the House Committee on Energy and Commerce.
lower
Mar 9, 2022
Introduced
Introduced in House
lower
1 primary · 1 co-sponsor
Sponsors
Ask Maddy
·
AI policy assistant
Ask Maddy about HR 7032
Scope: US
Hi! I can help you understand HR 7032. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline